INSM Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
425.5M
+39.1%
306.0M
+16.0%
263.8M
+85.4%
142.3M
+32.5%
107.4M
Cost of Revenue
67.2M
+41.7%
47.4M
+7.2%
44.2M
+50.6%
29.4M
+4.6%
28.1M
Gross Profit
358.3M
+38.6%
258.5M
+17.7%
219.6M
+94.4%
113.0M
+42.4%
79.3M
Operating Expenses
359.8M
-12.6%
411.9M
-23.6%
539.4M
+12.6%
479.0M
+22.1%
392.2M
R&D
210.0M
+0.3%
209.5M
-17.8%
254.9M
+36.7%
186.4M
+5.2%
177.2M
SG&A
247.5M
+0.1%
247.3M
+16.4%
212.5M
+14.0%
186.4M
+20.4%
154.8M
Operating Income
-1548000
+99.0%
-153320000
+52.0%
-319748000
+12.6%
-366005000
-17.0%
-312876000
EBITDA
3.7M
+102.5%
-148305000
+52.8%
-314187000
+13.2%
-362009000
-17.1%
-309129000
Net Income
-13242000
+91.9%
-163563000
+50.2%
-328485000
+11.2%
-370021000
-15.0%
-321686000
EPS (Basic)
$-0.06
+92.1%
$-0.76
+50.3%
$-1.53
+12.6%
$-1.75
-2.9%
$-1.70
EPS (Diluted)
$-0.06
+92.1%
$-0.76
+50.3%
$-1.53
+12.6%
$-1.75
-2.9%
$-1.70
Shares (Diluted)
217.4M
+0.9%
215.5M
+0.6%
214.1M
+1.1%
211.8M
+11.9%
189.3M
Insmed (INSM) โ€” Financials